Nexcella, Inc. www.nexcella.com

immix42623

Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris

Format

JPEG

Source

Nexcella, Inc.

Downloads